Low-Dose Denosumab May Be Effective in Maintaining BMD in Postmenopausal Osteoporosis
Researchers evaluated the efficacy of low-dose denosumab for maintaining bone mineral density in postmenopausal women with osteoporosis.
Researchers evaluated the efficacy of low-dose denosumab for maintaining bone mineral density in postmenopausal women with osteoporosis.
Researchers investigated the effects of canagliflozin on serum urate levels and gout in patients with type 2 diabetes.
The study identified biomarkers for changes in bone mineral density at three anatomic sites in patients with osteoporosis secondary to RA.